Skip to main content
(617) 353-HELP
SCHEDULE A MEETING
JOIN A MEETING
HOST A MEETING
IS&T:
(617) 353-HELP
Zoom:
(888) 799-9666
SIGN IN
SIGN UP, IT'S FREE
SIGN UP, IT'S FREE
webinar register page
Topic
Improving Biomarker Driven Precision Therapy in NSCLC: Uncovering ALK in Clinical Practice: Physician, Pharmacist, and Patient Perspectives
Description
The overall goal of this project is to help identify critical gaps in standard biomarker testing and help improve understanding of targeted therapies for patients with non-small cell lung cancer (NSCLC). Furthermore, this educational series would allow oncology team members to become more familiar with the targeted approaches for less common mutations and make treatment decisions to promote better care for patients. Biomarker based testing and precision medicine based approaches have become a standard to guide treatment decisions for metastatic non-small cell lung cancer (NSCLC) and are crucial even for early stage/resected patients. There are several barriers that prevent optimal testing for patients, but the discovery of novel molecular targets and subsequent development of targeted therapies make it critical to find ways to overcome these barriers. As treatment progresses, there is a potential to develop resistance mechanisms to commonly used targeted therapies; these new targets are identified by the integration of precision medicine. It is imperative for all members of the lung cancer treatment team (oncologists, pathologists, pharmacists, nurse practitioners, nurses, and physicians’ assistants) and even patients to understand this data and recognize the complexity of managing these patients using a precision medicine based approach in both first line and subsequent line therapies.
This webinar will be a roundtable discussion with a pharmacist, oncologist, and patient to identify clinical pearls and best practices for ALK-rearranged NSCLC. We will focus on:
• Overcoming barriers and differences of biomarker testing
• Reviewing ALK-rearrangements and first line therapy in mNSCLC
• Perspective on re-biopsy at progression and subsequent treatment based on resistance
This program is supported by an educational grant from Pfizer.
More detailed information including continuing education credit information can be found at: https://cme.bu.edu/NSCLCpart4
Time
May 10, 2022 05:00 PM in
Eastern Time (US and Canada)
Webinar is over, you cannot register now. If you have any questions, please contact Webinar host:
Continuing Medical Education
.
×
Share via Email
All fields are required
Your Information
Send to
Message preview
Hi there, You are invited to a Zoom webinar. When: May 10, 2022 05:00 PM Eastern Time (US and Canada) Topic: Improving Biomarker Driven Precision Therapy in NSCLC: Uncovering ALK in Clinical Practice: Physician, Pharmacist, and Patient Perspectives Register in advance for this webinar: https://bostonu.zoom.us/webinar/register/WN_yLZEISCvQ1KBHrdqn7y5sw Or an H.323/SIP room system: H.323: 162.255.37.11 (US West) 162.255.36.11 (US East) 221.122.88.195 (China) 115.114.131.7 (India Mumbai) 115.114.115.7 (India Hyderabad) 213.19.144.110 (Amsterdam Netherlands) 213.244.140.110 (Germany) 103.122.166.55 (Australia Sydney) 103.122.167.55 (Australia Melbourne) 209.9.211.110 (Hong Kong SAR) 149.137.40.110 (Singapore) 64.211.144.160 (Brazil) 149.137.68.253 (Mexico) 69.174.57.160 (Canada Toronto) 65.39.152.160 (Canada Vancouver) 207.226.132.110 (Japan Tokyo) 149.137.24.110 (Japan Osaka) Meeting ID: 977 9063 3639 SIP: 97790633639@zoomcrc.com After registering, you will receive a confirmation email containing information about joining the webinar. ---------- Webinar Speakers David Hughes, PharmD, BCOP (Clinical Pharmacy Manager Hematology/Oncology @Boston Medical Center) Jasmine Patel, PharmD (Clinical Pharmacy Specialist – Hematology/Oncology @Boston Medical Center) Umit Tapan, MD (Assistant Professor of Medicine, Department of Medicine @Boston University School of Medicine) Kirk Smith (Patient, 8.5 years living with Stage 4 ALK Positive lung cancer )
×
Switch Time Zone
Time Zone:
(GMT-11:00) Midway Island, Samoa
(GMT-11:00) Pago Pago
(GMT-10:00) Hawaii
(GMT-8:00) Alaska
(GMT-8:00) Juneau
(GMT-7:00) Vancouver
(GMT-7:00) Pacific Time (US and Canada)
(GMT-7:00) Tijuana
(GMT-7:00) Arizona
(GMT-7:00) Yukon
(GMT-6:00) Edmonton
(GMT-6:00) Mountain Time (US and Canada)
(GMT-6:00) Mazatlan
(GMT-6:00) Saskatchewan
(GMT-6:00) Guatemala
(GMT-6:00) El Salvador
(GMT-6:00) Managua
(GMT-6:00) Costa Rica
(GMT-6:00) Tegucigalpa
(GMT-6:00) Chihuahua
(GMT-5:00) Winnipeg
(GMT-5:00) Central Time (US and Canada)
(GMT-5:00) Mexico City
(GMT-5:00) Panama
(GMT-5:00) Bogota
(GMT-5:00) Lima
(GMT-5:00) Monterrey
(GMT-5:00) Acre
(GMT-4:00) Montreal
(GMT-4:00) Eastern Time (US and Canada)
(GMT-4:00) Indiana (East)
(GMT-4:00) Puerto Rico
(GMT-4:00) Caracas
(GMT-4:00) Santiago
(GMT-4:00) La Paz
(GMT-4:00) Guyana
(GMT-3:00) Halifax
(GMT-3:00) Montevideo
(GMT-3:00) Recife
(GMT-3:00) Buenos Aires, Georgetown
(GMT-3:00) Sao Paulo
(GMT-3:00) Atlantic Time (Canada)
(GMT-2:30) Newfoundland and Labrador
(GMT-2:00) Greenland
(GMT-2:00) Fernando de Noronha
(GMT-1:00) Cape Verde Islands
(GMT+0:00) Azores
(GMT+0:00) Universal Time UTC
(GMT+0:00) Greenwich Mean Time
(GMT+0:00) Reykjavik
(GMT+0:00) Nouakchott
(GMT+1:00) Casablanca
(GMT+1:00) Dublin
(GMT+1:00) London
(GMT+1:00) Lisbon
(GMT+1:00) West Central Africa
(GMT+1:00) Algiers
(GMT+1:00) Tunis
(GMT+2:00) Belgrade, Bratislava, Ljubljana
(GMT+2:00) Sarajevo, Skopje, Zagreb
(GMT+2:00) Oslo
(GMT+2:00) Copenhagen
(GMT+2:00) Brussels
(GMT+2:00) Amsterdam, Berlin, Rome, Stockholm, Vienna
(GMT+2:00) Amsterdam
(GMT+2:00) Rome
(GMT+2:00) Stockholm
(GMT+2:00) Vienna
(GMT+2:00) Luxembourg
(GMT+2:00) Paris
(GMT+2:00) Zurich
(GMT+2:00) Madrid
(GMT+2:00) Harare, Pretoria
(GMT+2:00) Warsaw
(GMT+2:00) Prague Bratislava
(GMT+2:00) Budapest
(GMT+2:00) Tripoli
(GMT+2:00) Cairo
(GMT+2:00) Johannesburg
(GMT+2:00) Khartoum
(GMT+3:00) Helsinki
(GMT+3:00) Nairobi
(GMT+3:00) Sofia
(GMT+3:00) Istanbul
(GMT+3:00) Athens
(GMT+3:00) Bucharest
(GMT+3:00) Nicosia
(GMT+3:00) Beirut
(GMT+3:00) Damascus
(GMT+3:00) Jerusalem
(GMT+3:00) Amman
(GMT+3:00) Moscow
(GMT+3:00) Baghdad
(GMT+3:00) Kuwait
(GMT+3:00) Riyadh
(GMT+3:00) Bahrain
(GMT+3:00) Qatar
(GMT+3:00) Aden
(GMT+3:00) Djibouti
(GMT+3:00) Mogadishu
(GMT+3:00) Kiev
(GMT+3:00) Minsk
(GMT+3:00) Chisinau
(GMT+4:00) Dubai
(GMT+4:00) Muscat
(GMT+4:00) Baku, Tbilisi, Yerevan
(GMT+4:30) Tehran
(GMT+4:30) Kabul
(GMT+5:00) Yekaterinburg
(GMT+5:00) Islamabad, Karachi, Tashkent
(GMT+5:30) India
(GMT+5:30) Mumbai, Kolkata, New Delhi
(GMT+5:30) Colombo
(GMT+5:45) Kathmandu
(GMT+6:00) Almaty
(GMT+6:00) Dacca
(GMT+6:00) Astana, Dhaka
(GMT+6:30) Rangoon
(GMT+7:00) Novosibirsk
(GMT+7:00) Krasnoyarsk
(GMT+7:00) Bangkok
(GMT+7:00) Vietnam
(GMT+7:00) Jakarta
(GMT+8:00) Irkutsk, Ulaanbaatar
(GMT+8:00) Beijing, Shanghai
(GMT+8:00) Hong Kong SAR
(GMT+8:00) Taipei
(GMT+8:00) Kuala Lumpur
(GMT+8:00) Singapore
(GMT+8:00) Perth
(GMT+9:00) Yakutsk
(GMT+9:00) Seoul
(GMT+9:00) Osaka, Sapporo, Tokyo
(GMT+9:30) Darwin
(GMT+9:30) Adelaide
(GMT+10:00) Vladivostok
(GMT+10:00) Guam, Port Moresby
(GMT+10:00) Brisbane
(GMT+10:00) Canberra, Melbourne, Sydney
(GMT+10:00) Hobart
(GMT+10:30) Lord Howe IsIand
(GMT+11:00) Magadan
(GMT+11:00) Solomon Islands
(GMT+11:00) New Caledonia
(GMT+12:00) Kamchatka
(GMT+12:00) Fiji Islands, Marshall Islands
(GMT+12:00) Auckland, Wellington
(GMT+13:00) Independent State of Samoa
×
Continue to PayPal
Click to Continue
×
×
Upcoming Meetings
Would you like to start this meeting?
Would you like to start one of these meetings?
View more...